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Peroxisome proliferator-activated receptor Gamma responsible for
TGFb-induced epithelial mesenchymal transition (EMT) and tumor
invasion of NSCLC cells (H460)
L.C. Lin1, S.L. Hsu2, C.L. Wu3, W.C. Liu1, H.T. Chiu1, C.M. Hsueh1.
1National Chung Hsing University, Department of Life Sciences, Taichung
city, Taiwan; 2Taichung Veterans General Hospital, Department of
Education and Research, Taichung city, Taiwan; 3Taichung Veterans
General Hospital, Department of Internal Medicine, Taichung city, Taiwan
We have previously demonstrated that non-small cell lung cancer cell,
H460, had strong drug resistance to TGFb and can grow and metastasize
successfully in animal model. Despite the fact TGFb can suppress
the growth of gastric carcinoma and hepatoma cells, it also promotes
the epithelial mesenchymal transition (EMT) and/or metastasis of liver
and breast cancers. We therefore were interested to know would
TGFb also promote the EMT and invasion in NSCLC cells (H460)
and exacerbate tumor metastasis. TGFb-triggered signaling pathway,
P38/ERK/cPLA2a/COX-2, and its downstream target, PPARg were also
analyzed in H460 with or without TGFb to link with the induced EMT and/or
tumor invasion. According to our early observation, PPARg was already
known to play a critical role in the early development of TGFb resistance
of H460. Our current results showed that TGFb-induced cell scattering
of H460 ﬁrst appeared at day 3 after the TGFb treatment followed by a
morphological shift (from round to ﬁbroblast or spindle-like shape) at day 7
and 14. The results clearly demonstrated a TGFb-induced EMT in H460.
Seven days after TGFb treatment, the migration and invasion of H460 were
signiﬁcantly increased in accompany with the induced expression of PPARg
and cell survival. The up-stream regulators (P38, ERK, cPLA2a and COX-
2) of PPARg were also activated (phosphorylated) by TGFb at early time
points (1−6 h). To further conﬁrm the role of PPARg in TGFb-induced EMT
and cell invasion in H460, we added PPARg inhibitor (GW9662) into TGFb-
treated H460 and found that not only survival of H460 was decreased,
TGFb-induced EMT and cell invasion were also interrupted. The results
suggested that PPARg was critical in the protection of H460 from TGFb-
mediated growth inhibition and also promoted TGFb-induced EMT and cell
invasion in H460. In overall, TGFb-induced EMT and cell invasion in H460
have been conﬁrmed and proved to be PPARg dependent. Results from
the study not only provided information about the drug resistance and
metastasis of H460 in response to TGFb treatment but also implied the
therapeutic value of PPARg inhibitor (GW9662) in the treatment of NSCLCs.
1212 POSTER
A novel mitotic kinesin Eg5 inhibitor exerts the growth inhibitory
effect on cancer cells in a manner independent of neither Eg5
expression level nor induction of monoastral formation
H. Lee1, N. Ogo2, A. Asai2, N. Boku3, Y. Koh1. 1Shizuoka Cancer Center
Research Institute, Drug Discovery and Development Division, Shizuoka,
Japan; 2Graduate School of Pharmaceutical Sciences University of
Shizuoka, Center for Drug Discovery, Shizuoka, Japan; 3Shizuoka Cancer
Center, Gatrointestinal Division, Shizuoka, Japan
Background: Mitotic kinesin Eg5 plays an important role in mitosis, as it is
critical for proper bipolar spindle assembly. After the discovery of the ﬁrst
Eg5 inhibitor monastrol, a number of Eg5 inhibitors have been developed
as anticancer drugs. We have synthesized a series of S-trityl-L-cysteine
(STLC) derivatives as Eg5 inhibitors and showed potent growth inhibitory
effect on cancer cells and induction of monoastral formation.
Materials and Methods: Growth inhibitory effects of monastrol and STLC
derivatives, Compound1, Compound2 and Compound3 were evaluated by
MTT assay in MKN1, MKN45, MKN74, NUGC3, NUGC4, NCI-N87 gastric
cancer cell lines, C170, DLD1, HCT15, COLO205 colon cancer cell lines
and AsPC1, BxPC3, SUIT2 pancreatic cancer cell lines. Cell cycle analysis
and immunocytochemistry were carried out to evaluate the induction of
mitotic arrest and monoastral formation, respectively. Expression levels of
Eg5, BubR1 and MAD2 were evaluated by western blot for a predictive
biomarker study.
Results: Among the derivatives, Compound3 showed the most potent
growth inhibitory effect with IC50 s ranging from 0.16 to 0.89mM except for
AsPC3 cells, while monastrol showed almost no effect at concentrations
up to 10mM. Compound3 induced G2/M arrest as early as 8 hours after
the treatment at a concentration of IC50. Induction of monoastral formation
was modestly observed in BxPC3 and HCT15 cells which are sensitive
to, Compound3, while it was also observed in AsPC3 cells which are
not sensitive to Compound3 with an IC50 of around 10mM. There was
no correlation observed between the growth inhibitory effect and the Eg5
expression level and no signiﬁcant change was observed in the BubR1 or
MAD2 expression level after the treatment, either.
Conclusions: It is suggested that Compound3 should be considered
for further exploration and development and that induction of monoastral
formation may not work as a predictive biomarker. Taken together, a novel
mitotic kinesin Eg5 inhibitor Compound3 may have other mechanisms of
action for its growth inhibitory effect on cancer cells and further investigation
on alternative biomarkers is necessary to develop Eg5 inhibitors as an
anticancer drug.
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Plumbagin induces ROS-mediated apoptosis in human myeloid
leukaemia cells in vivo
K.H. Xu1, D.P. Lu1. 1Institute of Hematology, Peking University, Beijing,
China
Plumbagin, a naphtoquinone from the roots of Plumbago zeylanica, known
to possess anticancer and antibacterial activity. Based on the former
ﬁnding in vitro, we further investigated the effects of Plumbagin on the
growth of human myeloid leukemia NB4 cells that had been transplanted
subcutaneously into NOD/SCID mice.
Material and Methods: In order to elucidate the molecular mechanism
involved in plumbagin-induced apoptosis. we studied the effect of
Plumbagin with IC50 (9 uM) by monitoring the activity of the caspase-3
and caspase-9, the change of mitochondrial membrane potential (DYm),
the expression of the Bcl-2 family as well as ROS change in plumbagin-
induced apoptosis. The efﬁcacy of Plumbagin in vivo was evaluated with
intraperitoneal injection of plumbagin (2mg/kg body weight) daily for three
weeks using subcutaneous NB4 xenograft in NOD/SCID mice, comparing
with the vehicle and Doxorubicin (1mg/kg thrice a week). The tissue
sections were applied to hematoxylin and eosin histological staining as
well as TUNEL assay.
Results:We revealed that plumbagin triggered the mitochondrial apoptotic
pathway, as indicated by the increase in Bax/Bcl-2 ratios, resulting
in mitochondrial membrane potential loss, and corresponding caspase
activation. We also found that the generation of ROS was a critical
mediator in plumbagin-induced cell apoptosis, which would be abrogated
completely by the antioxidant, NAC. Furthermore, compared with the
control, Plumbagin presented a ~60% reduction of tumor volume and
marked increase in tumor apoptosis; There was no overt manifestation
of toxicity such as weight loss, tissue damage and behavior change as
showed in Doxorubicin -treated mice.
Conclusion: Our data support that Plumbagin has potential as a novel
therapeutic agent for myeloid leukemia with minimal side-effects.
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Anti-cancer effects of artesunate in a panel of chemoresistant
neuroblastoma cell lines
M. Michaelis1, M.C. Kleinschmidt1, S. Barth2, R. Breitling3, B. Mayer4,
H. Deubzer5, O. Witt5, H.W. Doerr1, J. Cinatl1, J. Cinatl Jr.1.
1Universitatsklinikum, Institut Fu¨r Medizinische Virologie, Frankfurt
Am Main, Germany; 2Blue-Drugs Gmbh, Research, Frankfurt Am
Main, Germany; 3University Of Groningen, Groningen Bioinformatics
Center, Groningen, The Netherlands; 4Emergentec Biodevelopment
Gmbh, Research, Vienna, Austria; 5DKFZ, Klinische Kooperationseinheit
Pa¨diatrische Onkologie (g340) and Pa¨diatrie III, Heidelberg, Germany
Background: Artemisinin derivatives are well-tolerated anti-malaria drugs
that also exert anti-cancer activity. Here, we investigated artemisinin and its
derivatives dihydroartemisinin and artesunate in a panel of chemosensitive
and chemoresistant human neuroblastoma cells as well as in primary
neuroblastoma cultures.
Materials and Methods: Cell viability was determined by MTT assay or by
determination of ATPase activity. Apoptosis was examined by staining for
activated caspase-3 and detection of cells with low DNA content (sub-G1)
by ﬂow cytometry. Bioinformatic analysis of gene microarray data was used
to identify genes relevant fr neuroblastoma cell response to artesunate.
Results: Only dihydroartemisinin and artesunate affected neuroblastoma
cell viability with artesunate being more active. Of 16 cell lines and
two primary cultures, only UKF-NB-3rCDDP1000 showed low sensitivity to
artesunate. Artesunate induced apoptosis and reactive oxygen species
in neuroblastoma cells. L-Buthionine-S,R-sulfoximine, an inhibitor of GCL
(glutamate-cysteine ligase), resensitised in part UKF-NB-3rCDDP1000
cells to artesunate. This ﬁnding together with bioinformatic analysis of
expression of genes involved in glutathione metabolism showed that this
pathway is involved in artesunate resistance.
Conclusion: These data indicate that neuroblastoma represents a
artesunate-sensitive cancer entity including chemoresistant cells. Char-
acteristic gene expression signatures based on a previous analysis of
artesunate resistance in the NCI60 cell line panel clearly separated UKF-
NB-3rCDDP1000 from the other cell lines.
